Putting a value on medical research

Lancet

Volumn 367, Issue 9519, 2006, Pages 1293-1295

  Blakemore, Colin ^a   Davidson, John ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOMYCIN;

ADVERTIZING; ARTICLE; BED REST; CANADA; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; LUNG CANCER; LUNG TUBERCULOSIS; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDICINE; PRIORITY JOURNAL; SOCIAL ATTITUDE; SOCIOECONOMICS; STROKE; THROMBOEMBOLISM; UNITED KINGDOM; UNITED STATES;

EID: 33646025215     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68552-8     Document Type: Note

References (17)

1. Academy of Medical Sciences, Medical Research Council, Wellcome Trust. Medical research: assessing the benefits to society. A Report by the UK Evaluation Forum. London: Academy of Medical Sciences (in press).
2. Johnston S., Rootenberg J., Katrak S., Smith W., and Elkins J. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 357 (2006) 1319-1327
3. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ 2 (1948) 769-782
4. Crofton J. The MRC randomised trial of streptomycin and its legacy: a view from the clinical front line. The James Lind Library (2004). http://www.jameslindlibrary.org/trial_records/20th_Century/1940s/MRC_bmj/crofton.html (accessed April 16, 2006)
5. Frederickson D. Sorting out the doctor's bag. Control Clin Trials 1 (1980) 263-267
6. Cutler D., and McClellan M. Is technological change in medicine worth it?. Health Affairs 20 (2001) 11-29
7. Funding First. Exceptional returns: the economic value of America's investment in medical research (2000), Mary Woodward Lasker Charitable Trust, New York, NY. http://www.laskerfoundation.org/reports/pdf/exceptional.pdf (accessed April 16, 2006)
8. In: Murphy K., and Topel R. (Eds). Measuring the gains from medical research: an economic approach (2003), University of Chicago Press, Chicago
9. Access Economics. Exceptional returns, the value of investing in health R&D in Australia (2003), Australian Society for Medical Research, Canberra. http://www.researchaustralia.com.au/files/Access_Economics_Exceptional_Returns.pdf (accessed April 16, 2006)
10. Rosenberg L. Exceptional economic returns on investments in medical research. Med J Aust 177 (2002) 368-371
11. Sazanov L., and Hinchliffe P. Structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus. Science 311 (2006) 1430-1436
12. Slovic P. Trust, emotion, sex, politics, and science: surveying the risk-assessment battlefield. Risk Analysis 19 (1999) 689-701
13. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338 (1991) 131-137
14. Oakley G. Delaying folic acid fortification of flour. BMJ 324 (2002) 1348-1389
15. Lewis C., Pancharuniti N., and Sauberlich H. Plasma folate adequacy as determined by homocysteine level. Ann NY Acad Sci 669 (1992) 360-362
16. Martin J., Smith B., Mathews T., and Ventura M. Births and deaths: preliminary data for 1998. National Vital Statistics Reports 47 (1999) 1-48
17. Doll R., and Hill A. Smoking and carcinoma of the lung; preliminary report. BMJ 2 (1950) 739-748